Table 2:

Univariate and multivariate analysis of OS in 125 patients with primary GIST undergoing Neo-IM.

	Univariate					Multivariatea
Parameter	Class Value	Reference	HR	CI	p-value	HR	CI	p-value
Age at first surgery (yrs)	N/A	N/A	1.04	1.01–1.06	0.009	1.05	1.01–1.09	0.013
Sex	M	F	1.62	0.81–3.25	0.18
Primary tumor site	Small Bowel	Stomach	1.67	0.80–3.52	0.18
	Rectum	Stomach	0.42	0.06–3.23	0.41
	Other	Stomach	3.01	1.20–7.53	0.019
Primary tumor size (cm)	>10	<=5	1.59	0.54–4.64	0.40
	5–10	<=5	1.29	0.40–4.23	0.67
Histologic variant	Epithelioid	Spindle	1.18	0.44–3.16	0.74
	Mixed	Spindle	1.55	0.65–3.67	0.32
Margin	R1	R0	1.69	0.70–4.10	0.24	2.33	0.78–6.93	0.13
	R2	R0	3.98	1.89–8.37	<.001	6.00	2.32–15.5	<0.001
Primary tumor post-treatment mitotic rate per 50 HPF	>5	≤5	4.14	2.10–8.16	<.001	5.34	3.30–12.4	<0.001
Primary tumor viability	>50%	≤50%	1.61	0.80–3.25	0.18	1.20	0.48–3.00	0.69
Primary tumor mRECIST	PD	SD	1.14	0.38–3.40	0.82	0.34	0.04–2.73	0.31
	PR	SD	1.00	0.49–2.08	>0.95	0.72	0.32–1.61	0.43
Synchronous metastases	Synch met	No synch	1.52	0.78–2.97	0.22
Adjuvant imatinib	Yes	No	0.46	0.24–0.91	0.026	0.41	0.19–0.89	0.025

^aOnly the final multivariate model is shown.